The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

被引：520

作者：

Yuan, Min ^{[1
,2
]}

Huang, Li-Li ^{[1
,2
]}

Chen, Jian-Hua ^{[1
,3
]}

Wu, Jie ^{[3
,4
]}

Xu, Qing ^{[1
,2
]}

机构：

[1] Tongji Univ, Dermatol Hosp, Dept Oncol, Sch Med, Shanghai 200443, Peoples R China

[2] Tongji Univ, Shanghai Peoples Hosp 10, Dept Oncol, Sch Med, Shanghai 200072, Peoples R China

[3] Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK 73104 USA

[4] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA

来源：

SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2019年 / 4卷 / 1期

基金：

中国国家自然科学基金;

关键词：

EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE INHIBITORS; ANTI-HER3; MONOCLONAL-ANTIBODY; NIVOLUMAB PLUS IPILIMUMAB; RECEPTOR GENE-MUTATIONS; RANDOMIZED PHASE-III; OPEN-LABEL; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; EGFR MUTATIONS;

D O I：

10.1038/s41392-019-0099-9

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Lung cancer is one of the most common cancer in the world. In 2018, there were over 2 million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer. Targeted therapy has emerged as an important mean of the disease management for patients with non-small-cell lung cancer (NSCLC). Herein, we review and analyze recent literature, discuss the targeting pathways and ongoing clinical trials in lung cancer. Chemotherapy is no longer the best available treatment for all patients. Therapeutic decisions should be guided by an understanding of the molecular features of patient's tumor tissues. The future gains will likely emerge from finding optimal ways of combining targeted therapy, immunotherapy, and chemotherapy.

引用

页数：14

共 160 条

[61] Clinical development of HER3-targeting monoclonal antibodies: Perils and progress [J].

Jacob, Wolfgang ;

James, Ian ;

Hasmann, Max ;

Weisser, Martin .

CANCER TREATMENT REVIEWS, 2018, 68 :111-123

[62] Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations [J].

Janjigian, Yelena Y. ;

Park, Bernard J. ;

Zakowski, Maureen F. ;

Ladanyi, Marc ;

Pao, William ;

D'Angelo, Sandra P. ;

Kris, Mark G. ;

Shen, Ronglai ;

Zheng, Junting ;

Azzoli, Christopher G. .

JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (03) :569-575

[63] ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer [J].

Johnson, Bruce E. ;

Kabbinavar, Fairooz ;

Fehrenbacher, Louis ;

Hainsworth, John ;

Kasubhai, Saifuddin ;

Kressel, Bruce ;

Lin, Chin-Yu ;

Marsland, Thomas ;

Patel, Taral ;

Polikoff, Jonathan ;

Rubin, Mark ;

White, Leonard ;

Yang, James Chih-Hsin ;

Bowden, Chris ;

Miller, Vincent .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (31) :3926-+

[64] HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy [J].

Kawakami, Hisato ;

Yonesaka, Kimio .

RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2016, 11 (03) :267-274

[65] PIK3CA mutation status in Japanese lung cancer patients [J].

Kawano, Osamu ;

Sasaki, Hidefumi ;

Endo, Katsuhiko ;

Suzuki, Eriko ;

Haneda, Hiroshi ;

Yukiue, Haruhiro ;

Kobayashi, Yoshihiro ;

Yano, Motoki ;

Fujii, Yoshitaka .

LUNG CANCER, 2006, 54 (02) :209-215

[66] Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial [J].

Kelly, Karen ;

Altorki, Nasser K. ;

Eberhardt, Wilfried E. E. ;

O'Brien, Mary E. R. ;

Spigel, David R. ;

Crino, Lucio ;

Tsai, Chun-Ming ;

Kim, Joo-Hang ;

Cho, Eun Kyung ;

Hoffman, Philip C. ;

Orlov, Sergey V. ;

Serwatowski, Piotr ;

Wang, Jiuzhou ;

Foley, Margaret A. ;

Horan, Julie D. ;

Shepherd, Frances A. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) :4007-+

[67] Non-Small Cell Lung Cancer, PD-L1, and the Pathologist [J].

Kerr, Keith M. ;

Nicolson, Marianne C. .

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2016, 140 (03) :249-254

[68] Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer [J].

Kim, Soyeon ;

Kim, Tae Min ;

Kim, Dong-Wan ;

Go, Heounjeong ;

Keam, Bhumsuk ;

Lee, Se-Hoon ;

Ku, Ja-Lok ;

Chung, Doo Hyun ;

Heo, Dae Seog .

JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (04) :415-422

[69] Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor [J].

Kim, Woo-Jin ;

Kim, Sunmin ;

Choi, Hayoung ;

Chang, Jinsun ;

Shin, Hong-Joon ;

Park, Cheol-Kyu ;

Oh, In-Jae ;

Kim, Kyu-Sik ;

Kim, Young-Chul ;

Choi, Yoo-Duk .

THORACIC CANCER, 2015, 6 (06) :800-804

[70] Protein inhibitor of activated STAT3 expression in lung cancer [J].

Kluge, Amy ;

Dabir, Snehal ;

Vlassenbroeck, Ilse ;

Eisenberg, Rosana ;

Dowlati, Afshin .

MOLECULAR ONCOLOGY, 2011, 5 (03) :256-264

← 2 3 4 5 6 7 8 9 10 11 →